UroGen Pharma (FRA:UR8) Dividends per Share: €0.00 (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:UR8 UroGen Pharma Ltd FRA:UR8
60 GF Score
Price €35.07
GF Value €20.40
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is UroGen Pharma Dividends per Share?

UroGen Pharma FRA:UR8 +1.53% 60 Dividends per Share is €0.00 as of Mar. 2026. GuruFocus rates FRA:UR8 with a GF Score™ of 60/100 and a GF Value™ of €20.40 (Significantly Overvalued). The stock has 10 warning signs investors should review.

UroGen Pharma's dividends per share for the three months ended in Mar. 2026 was €0.00. Its dividends per share for the trailing twelve months (TTM) ended in Mar. 2026 was €0.00. Its Dividend Payout Ratio for the three months ended in Mar. 2026 was 0.00. As of today, UroGen Pharma's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.

UroGen Pharma  (FRA:UR8) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

UroGen Pharma's Dividend Payout Ratio for the quarter that ended in Mar. 2026 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Mar. 2026 )/ EPS without NRI (Q: Mar. 2026 )
=0/ -0.407
=N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

UroGen Pharma Dividends per Share Related Terms

UroGen Pharma Dividends per Share Historical Data

* Premium members only.

The historical data trend for UroGen Pharma's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

UroGen Pharma Dividends per Share Chart

UroGen Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Dividends per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

UroGen Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Dividends per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:UR8 vs PVLA, AUPH, RAPP: Dividends per Share Comparison

For the Biotechnology subindustry, UroGen Pharma's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

UroGen Pharma Dividend Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, UroGen Pharma's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where UroGen Pharma's Dividend Yield % falls into.


FRA:UR8
60GF Score
UroGen Pharma Ltd FRA:UR8
Dividends per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

UroGen Pharma Dividends per Share Calculation

Dividends paid to per common share.

Frequently Asked Questions Learn more about Dividends per Share →
What does a Dividends per Share of €0.00 mean?
UroGen Pharma (FRA:UR8) has a Dividends per Share of €0.00 as of Mar. 2026. Dividends per share represents the per-share amount paid as dividends. View historical data on UroGen Pharma and its competitors.
Is UroGen Pharma's Dividends per Share too high?
UroGen Pharma's current Dividends per Share is €0.00. Overall, UroGen Pharma has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does UroGen Pharma's Dividends per Share compare to PVLA and AUPH?
UroGen Pharma's Dividends per Share of €0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividends per Share for a Biotechnology company?
A good Dividends per Share depends on the Biotechnology industry context. However, Dividends per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividends per Share mean?
A high Dividends per Share can signal that a stock is expensive relative to its fundamentals. Dividends per share represents the per-share amount paid as dividends. View historical data on UroGen Pharma and its competitors. UroGen Pharma's current Dividends per Share is €0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UroGen Pharma stock overvalued right now?
Based on GuruFocus' analysis, UroGen Pharma (FRA:UR8) is currently considered Significantly Overvalued. The stock's GF Value™ is €20.40, compared to a current price of €35.07 — trading 71.9% above its estimated fair value. The current Dividends per Share is €0.00. UroGen Pharma's overall GF Score™ is 60/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividends per Share calculated?
Dividends per Share is calculated from a company's financial statements. For UroGen Pharma (FRA:UR8), the current Dividends per Share is €0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is UroGen Pharma (FRA:UR8) Overvalued in 2026?

Based on GuruFocus' analysis, UroGen Pharma stock appears to be overvalued. The current stock price of €35.07 is trading 71.9% above its estimated GF Value™ of €20.40. GuruFocus considers UroGen Pharma to be Significantly Overvalued.

Key valuation signals for FRA:UR8:

  • Dividends per Share: €0.00
  • GF Value™: €20.40 vs. price of €35.07 (71.9% above fair value)
  • GF Score™: 60/100 with 10 warning signs

No single metric tells the full story. See the FRA:UR8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

UroGen Pharma Business Description

Other Exchanges URGN:USA0XOD:UK
Address 400 Alexander Park Drive, 4th Floor, Princeton, NJ, USA, 08540
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
60GF Score

Get the complete analysis for FRA:UR8

Dividends per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€35.07
Price
€20.40
GF Value